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Abstract 1 
Anti-PD-1 therapy can induce eradication of tumors and immune-related adverse events (irAEs) in 2 
humans and model animals. However, how anti-PD-1 therapy modifies cellular phenotypes of CD8+ T 3 
cells to destroy tumors and damage self-tissues remains to be clarified. Here we performed single-cell 4 
mRNA expression profiling of autoreactive CD8+ T cells under or beyond PD-1 suppression in target 5 
tissues and reconstructed their activation trajectory. Autoreactive CD8+ T cells went through four 6 
activation phases and PD-1 strongly attenuated the transition from the second- to the third-phase, where 7 
effector functions were acquired. Shifts in cluster composition of autoreactive CD8+ T cells markedly 8 
reflected the severity of autoimmunity. In addition, genes up-regulated along the activation-trajectory in 9 
autoimmunity were highly expressed in responders of melanoma patients in anti-PD-1 therapy, 10 
suggesting that tumor-specific T cells need to be activated in a similar trajectory to destroy tumors in 11 
human patients upon PD-1 blockade. These findings reveal that PD-1 blockade facilitates the activation 12 
trajectory of CD8+ T cells to boost their effector functions. Targeted manipulation of the trajectory could 13 
lead to new therapeutic opportunities. 14 
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1. Introduction 1 
Due to the success of anti-PD-1 therapy in the treatment of cancer with the occasional development of 2 
immune-related adverse-events (irAEs), PD-1 is widely accepted as an immune-checkpoint receptor 3 
that serves to restrict immune responses against self-tissues and tumor cells [1-6]. However, it remains 4 
unclear how PD-1 modifies cellular phenotypes of T cell specific to self- and tumor-antigens to avoid 5 
autoimmunity and hamper tumor eradication.  6 
Engagement of PD-1 with either PD-L1 or PD-L2 during antigen stimulation results in the 7 
phosphorylation of two tyrosine residues in the cytoplasmic region of PD-1, the recruitment of protein 8 
tyrosine phosphatase, SHP-2 to the distal phospho-tyrosine, and the decreased phosphorylation of 9 
various signaling molecules. Thereby, PD-1 inhibits T cell receptor (TCR)-dependent activation of T 10 
cells to suppress their proliferation, cytokine production, and cytotoxicity [7-11]. Besides, PD-1 has 11 
been reported to induce anergy and exhaustion of T cells or instruct the differentiation of regulatory T 12 
cells [12-15]. Therefore, anti-PD-1 therapy is presumed to activate T cells by abrogating these PD-1 13 
functions in the eradication of tumors as well as destruction of self-tissues.  14 
Actually, PD-1 blockade has been shown to increase the number of antigen specific CD8+ T 15 
cells in mouse models of chronic viral infection [14-17]. These CD8+ T cells showed higher capacity to 16 
produce cytokines such as IFNγ and TNF upon ex vivo re-stimulation with antigen. However, the 17 
expression of effector molecules without ex vivo re-stimulation was marginal or transient, and thus how 18 
and where these CD8+ T cells acquire curative effector function upon PD-1 blockade remains to be 19 
elucidated. In the anti-PD-1 cancer immunotherapy, signatures of T cells such as activation, exhaustion, 20 
cytotoxicity, IFNγ response, and proliferation in tumor tissues have been shown to correlate with the 21 
outcome of the therapy [18-21]. However, the magnitude of up-regulation of individual genes upon 22 
anti-PD-1 therapy was limited or unspecified, making the actual activation status of T cells unintelligible. 23 
Riaz et al. estimated the number of each cell type in tumor tissues based on the gene expression profile 24 
by using an elaborated deconvolution method and demonstrated a positive correlation between the 25 
numbers of CD8+ T and NK cells to the outcome of anti-PD-1 therapy [21]. Huang et al. detected the 26 
proliferation of T cells in the peripheral blood upon anti-PD-1 therapy. Intriguingly, the proliferation of 27 
CD8+ T cells in relation to tumor burden showed a positive correlation to the outcome of anti-PD-1 28 
therapy, although the expression levels of Perforin and Granzymes in these proliferating CD8+ T cells 29 
were rather decreased upon anti-PD-1 therapy [22]. 30 
 Single cell analyses using mass cytometry and RNA sequencing are useful to estimate the states of 31 
individual cells and elucidate the cellular mechanisms of various biological phenomena. However, the 32 
activation of CD8+ T cells upon PD-1 blockade in tumor tissues or peripheral blood was not evident 33 
even with single cell analyses. The increase of CD8+ T cells with the exhausted signature or the lowest 34 
Gzmb expression among tumor-infiltrating lymphocytes has been reported as the hallmark of anti-PD-1 35 
therapy in single cell analyses using mass cytometry, which is rather paradoxical to its curative effects 36 
[23, 24]. By using single-cell RNA sequencing, the frequency of memory/effector-like CD8+ T cells in 37 
melanoma tissues was found to correlate with the outcome of anti-PD-1 therapy [25]. However, the 38 
difference likely represents the difference in tumors and microenvironments rather than the differential 39 
response to anti-PD-1 therapy among patients because the difference was not observed between 40 
samples before and after anti-PD-1 therapy [25]. Thus, the activation of CD8+ T cells upon anti-PD-1 41 
blockade has not been evident in former single cell analyses contrary to the general expectations, 42 
 4 
making the cellular mechanisms of tumor-eradication and irAEs by anti-PD-1 therapy remain unclear. 1 
 In the current study, we performed a quantitative PCR-based single-cell expression profiling and 2 
pseudotemporal analyses to explore the trajectory of autoreactive CD8+ T cells that are responsible for 3 
the fulminant type I diabetes (T1D) in NOD mice upon PD-1 blockade. First, we identified the 4 
trajectory of autoreactive CD8+ T cells with four distinct states. Next we found that autoreactive CD8+ T 5 
cells went through 4 activation phases. Remarkably, PD-1 strongly attenuated the transition from the 6 
second- to the third-phase, where effector functions were acquired. We further demonstrated that shifts 7 
in cluster composition markedly reflected severity of T1D in mouse. Finally, we analyzed the gene 8 
expression in melanomas of human patients. Genes representing functionally enabled T cells upon 9 
PD-1-blockade in T1D showed higher expression in melanoma tissues of responders after anti-PD-1 10 
therapy. Furthermore, genes representing active suppression by PD-1 in T1D showed higher expression 11 
in melanoma tissues of responders before anti-PD-1 therapy. These results suggest that tumor-specific T 12 
cells are activated in a similar trajectory as in T1D to destroy tumors in responders upon PD-1 blockade. 13 
 14 
2. Materials and methods 15 
2.1. Mice 16 
NOD/ShiJcl mice were purchased from Japan CLEA and housed under specific pathogen-free 17 
conditions in environmentally controlled clean rooms. All mouse protocols were approved by the 18 
Animal Experimentation Committee of Tokushima University. 19 
 20 
2.2. Induction of T1D 21 
Pre-diabetic female NOD mice (10 – 12 wks-old) were administrated intraperitoneally every other day 22 
with anti-PD-L1 Ab (1-111A, 500 µg)[26]. Mice were considered diabetic after two consecutive blood 23 
glucose measurements exceeded 250 mg/dL. Rat IgG2a (BioXCell) was used for control. CD4+ and 24 
CD8+ T cells were depleted by the intra venous injection of Abs against CD4 (GK1.5, 200 µg) and CD8 25 
(53-6.7, 200 µg) on days -3, 1, and 5.  26 
 27 
2.3. Isolation of islet-infiltrating lymphocytes 28 
Islet infiltrates were prepared from pre-diabetic NOD mice treated with or without anti-PD-L1 Ab as 29 
previously described [27]. Briefly, pancreata were dispersed into single-cell suspensions by collagenase 30 
(Wako) and DNase I (Sigma-Aldrich). Islet-infiltrating lymphocytes were enriched by Percoll gradient 31 
centrifugation (GE Healthcare). 32 
 33 
2.4. Detection of proliferating cells in mice  34 
Pre-diabetic NOD mice were treated with or without anti-PD-L1 Ab on days 0 and 2 and EdU 35 
(5-ethynyl-2'-deoxyuridine, 1mg) on day 2. Pancreatic infiltrates, pancreatic LN cells, and spleen cells 36 
were prepared on day 4. Ghost (TNBO, 13-0870) was used to distinguish live from dead cells. 37 
EdU-incorporated cells were detected using Click-iT™ Plus Alexa Fluor™ 647 Picolyl Azide Toolkit 38 
(InvitrogenTM) according to the manufacturer's instructions.  39 
 40 
2.5. Flowcytometric analysis 41 
Splenocytes, islet-infiltrating lymphocytes, and pancreatic LN cells were stained with indicated 42 
 5 
antibodies. Data were obtained with Gallios (Beckman Coulter) and analyzed using FlowJo (Tree Star) 1 
or CytoBnak (Cytobank). Fluorochrome-conjugated Abs against mouse CD3e (145-2C11), mouse 2 
TCRβ (H57-597), mouse CD8α (53–6.7), mouse CD4 (GK1.5 and RM4-5), mouse/human CD44 3 
(IM7), mouse CD45 (30-F11), mouse CD62L (MEL-14), mouse CD69 (H1.2F3), human/mouse/rat 4 
ICOS (C398.4A), mouse CD366 Tim-3 (RMT3-23), and mouse PD-1 (RMP1-30), biotinylated Abs 5 
against mouse/human CD11b (M1/70), mouse CD11c (N418), mouse CD45R/B220 (RA3-6B2), 6 
mouse Gr1 (RB6-8C5), mouse Ter-119 (TER-119), and mouse PD-1 (RMP1-30) mAb, and Brilliant 7 
Violet 421-conjugated streptavidin were purchased from Biolegend. PE-conjugated streptavidin was 8 
purchased from BD Pharmingen. Propidium Iodide was used to distinguish live from dead cells. 9 
 10 
2.6. Single cell expression profiling 11 
Islet-infiltrating lymphocytes were stained with biotinylated Abs against CD11b, CD11c, CD45R/B220, 12 
Gr1, and Ter-119 together with fluorochrome-conjugated Abs against CD8α, CD4, and PD-1. 13 
Biotinylated Abs were detected with streptavidin-BV421. PD-1+CD8+ T cells were sorted from 14 
islet-infiltrating lymphocytes using MoFlo XDP (Beckman Coulter). Single cells of sorted PD-1+CD8+ 15 
T cells were captured and lysed on chip using the C1 Single-Cell Auto Prep System (Fluidigm). Reverse 16 
transcription and pre-amplification of cDNA library were performed on chip according to the 17 
manufacturer’s instructions using a pool of 138 primer pairs specific to genes that are known to function 18 
in immune cells. Single-cell real-time quantitative PCR analyses were performed using nested primer 19 
pairs and 2x SsoFast EvaGreen Supermix with Low ROX (BioRad) in 96.96 Dynamic Array IFCs on 20 
the BioMark HD system (Fluidigm) according to the manufacturer’s instructions. Based on Ct values 21 
calculated by the Biomark software, expression levels of genes in each single cell were calculated 22 
(Supplemental dataset 1). Out of 178 cells, 3 cells with Gapdh expression values falling outside the 95% 23 
confidence interval were excluded from subsequent analyses. ANOVA was performed using the 24 
SINGuLAR Analysis Toolset v3.5.2 (Fluidigm). Heat maps, violin plots, and volcano plots were 25 
generated using the ggplot2 R package. PCA was performed using the ade4 R package. To cluster 26 
single cells, K-means++ clustering was performed using the LICORS R package. 27 
 28 
2.7. Pseudotemporal ordering 29 
The Monocle2 package was used to analyse trajectories of cells in order to discover activation 30 
transitions. ‘DDRTree’ was applied to reduce dimensions and the visualization functions 31 
‘plot_cell_trajectory’ or ‘plot_complex_cell_trajectory’ were used to plot the minimum spanning tree 32 
on cells. 33 
 34 
2.8. Dimentionality reduction 35 
Visual stochastic neighbour embedding (viSNE) analysis was performed on cytometry data using 36 
Cytobank (Cytobank). 37 
 38 
2.9. Quantitative PCR 39 
Total RNA was extracted from the single-cell suspension of pancreas using TRIzol (Ambion) and 40 
subjected to reverse transcription using High-Capacity cDNA Reverse Transcription Kit (Applied 41 
Biosystems). Gene expression was analyzed by quantitative PCR using Power SYBR Green PCR 42 
 6 
Master mix (Applied Biosystems) on a 7900HT Fast Real-time PCR (Applied Biosystems). Values 1 
were normalized to the expression of Gapdh. Specific primer sets are listed in Supplemental Table 1. 2 
 3 
2.10. Gene expression in human melanoma samples 4 
Normalized fragments per kilobase per million mapped reads (FPKM) of genes in human melanoma 5 
samples before or after the anti-PD-1 therapy with Nivolumab were obtained from Gene Expression 6 
Omnibus dataset (GSE91061). We examined the expression levels of genes that showed higher 7 
expression in C1–2 cells compared with C3–4 cells in human melanoma samples after the anti-PD-1 8 
therapy. We also examined the expression levels of genes that showed higher expression in C3–4 cells 9 
compared with C6 cells in human melanoma samples before the anti-PD-1 therapy. Patients were 10 
divided into responders (complete response, CR or partial response, PR), stable disease (SD), and 11 
non-responders (progressive disease, PD) according to the curative effects of anti-PD-1 therapy. 12 
Expression levels of genes were compared among three groups. Box plots were generated using the 13 
ggplot2 R package. 14 
 15 
2.11. Statistics.  16 
Two-tailed paired Student’s t-test was used to evaluate statistical significance unless otherwise indicated. 17 
p < 0.05 was considered statistically significant. 18 
 19 
3. Results 20 
3.1. CD8+ T cells are pathogenic in the fulminant T1D of NOD mice upon PD-1 blockade 21 
PD-1 persistently suppresses the activity of autoreactive T cells in pre-diabetic NOD mice as evidenced 22 
by the rapid induction of T1D upon PD-1-blockade with anti-PD-L1 Ab and the early onset of T1D in 23 
NOD-Pdcd1–/– mice (Fig. 1A)[28-30]. CD8+ T cells play the pathogenic role in this rapid manifestation 24 
of T1D because the depletion of CD8+ but not CD4+ T cells strongly attenuated the development of 25 
T1D upon PD-1-blockade (Fig. 1A). About 30% of islet-infiltrating CD8+ T cells in pre-diabetic NOD 26 
mice expressed PD-1, suggesting that these PD-1+CD8+ T cells were under the control of PD-1. Upon 27 
PD-1-blockade with anti-PD-L1 Ab, islet-infiltrating CD8+ T cells were rapidly activated to express 28 
PD-1 and start proliferation (Fig. 1B and Supplemental Fig. 1). These CD8+ T cells are beyond the 29 
control of PD-1 and likely included autoreactive CD8+ T cells that actively destroyed β cells. Although 30 
PD-1-expressing and proliferating CD8+ T cells were markedly increased in islets, their increases were 31 
insignificant or marginal in pancreatic LNs and spleen, suggesting that PD-1 mainly functions in target 32 
organs rather than in draining LNs in the regulation of autoreactive CD8+ T cells in NOD mice as 33 
suggested before (Supplemental Fig. 1)[30-32]. Therefore, we focused on islet-infiltrating PD-1+CD8+ 34 
T cells in the subsequent analyses. 35 
 36 
3.2. Clustering of autoreactive CD8+ T cells under or beyond the control of PD-1 37 
To characterize autoreactive CD8+ T cells under or beyond the control of PD-1, we prepared single 38 
PD-1+CD8+ T cells from pancreata of pre-diabetic NOD mice with or without PD-1-blockade 39 
(PD1posA and PD1posC cells for PD-1 positive cells of Ab-treated and control mice, respectively)(Fig. 40 
1B). Islet-infiltrating PD-1–CD8+ T cells from pre-diabetic NOD mice without PD-1-blockade were 41 
used as control (PD1negC cells). We evaluated the expression of 139 genes by quantitative PCR in a 42 
 7 
total of 175 single cells (PD1posA; 82 cells from 2 mice, PD1posC; 49 cells from 12 mice, and 1 
PD1negC; 44 cells from 9 mice) and clustered single cells into 6 groups (C1–6 clusters) by using 2 
k-means++ based on their gene expression profiles (C1; 14 cells, C2; 24 cells, C3; 28 cells, C4; 34 cells, 3 
C5; 35 cells, and C6; 40 cells) (Fig. 1C). To explore the molecular identities of single cells, we 4 
performed global principal component analysis (PCA) projection of all single cells profiled in this 5 
analysis. PD1posA, PD1posC and PD1negC cells were largely separated with substantial overlaps by 6 
PCA (Fig. 1D). We could also observe a clear separation of C1–6 cells by PCA (Fig. 1E). 7 
Activation-signature genes such as Cd44, Cd38, and Icos showed negative contribution to PC1 (Fig. 1F), 8 
suggesting that C1–4 cells represent activated cells and the magnitude of activation likely increase in the 9 
order of C4 to C1. Negative contribution of naive-signature genes such as Sell (CD62L), Ccr7, and Lef1 10 
to PC2 suggests that C5 cells represent naive cells. On the other hand, C6 cells had high PC1 and PC2 11 
values, suggesting that these cells represent antigen-experienced but inactivated cells that may resemble 12 
exhausted T (Tex) cells in chronic viral infection [33].  13 
 The composition of clusters largely differed among PD1posA, PD1posC, and PD1negC cells. 14 
Naive C5 cells predominated in PD1negC cells, in agreement with the activation-dependent expression 15 
of PD-1 (Fig. 1G)[34]. The frequencies of activated C1–C4 cells were largely differed between 16 
PD1posA and PD1posC cells (95% vs. 35% for PD1posA and PD1posC cells, respectively). 17 
Remarkably, activated PD1posC cells were composed of C3 and C4 cells, whereas PD1posA cells 18 
included C1 and C2 cells in addition to C3 and C4 cells, indicating that PD-1 restrains the transition 19 
from C3 to C2. More than half of PD1posC cells were clustered in C6, suggesting that these 20 
autoreactive CD8+ T cells were inactivated by PD-1 engagement (Fig. 1G).  21 
 22 
3.3. Delineation of the activation trajectory of autoreactive CD8+ T cells by pseudotemporal 23 
ordering 24 
To explore the continuum of activation states in autoreactive CD8+ T cells, we performed 25 
pseudotemporal ordering of the single cells by using Monocle 2 [35]. We could reconstruct a trajectory 26 
with two branches and four distinct states (Sa to Sd). We detected 69, 23, 44, and 39 cells on the path to 27 
Sa, Sb, Sc, and Sd, respectively (Fig. 2A–D and Supplemental Fig. S2A). C5 and C6 cells were 28 
concentrated at Sd and Sc tips of the tree, respectively, indicating that these cells are substantially distant 29 
from the other cells in pseudotime (Fig. 2, A, C, and D). As for activated C1–4 cells, C1–3 cells lined up 30 
on the path to Sa in this order, while the majority of C4 cells occupied the Sb tip of the tree. PD1posA 31 
cells were mainly composed of C1, C2, and C3 cells of Sa and C4 cells of Sb (Supplemental Fig. S2B). 32 
On the other hand, the majority of PD1posC and PD1negC cells were C6 cells of Sc and C5 cells of Sd, 33 
respectively (Supplemental Fig. S2B). The activation-signature of cells (expression levels of Cd44, 34 
Cd69, Cxcr3, Fasl, Gzma, Gzmb, Il2ra, and Tnf) showed progressive increase along the trajectory from 35 
Sb to Sa, suggesting that autoreactive CD8+ T cells were activated sequentially from Sb to Sa (Fig. 2E). 36 
In the trajectory from Sa to Sd, the naive-signature of cells (expression levels of Ccr7, Lef1, and Sell) 37 
was progressively increased toward Sd, confirming that Sd represents naive state (Fig. 2F). On the other 38 
hand, cells near Sc showed low naive- and activation-signatures, indicating that Sc represents 39 
inactivated state (Fig. 2G). 40 
 41 
3.4. PD-1 interrupts the activation trajectory of autoreactive CD8+ T cells to prohibit their 42 
 8 
acquisition of effector functions 1 
To further examine the activation trajectory of islet-infiltrating CD8+ T cells, we examined differentially 2 
expressed genes among different clusters. As expected, naive-signature genes were highly expressed in 3 
C5 cells, confirming that C5 represents migratory naive cells (Fig. 3A). When C1–4 cells were 4 
compared individually with C5 cells, the number of up-regulated genes was additively increased in the 5 
order of C4 to C1 (14, 43, 77, and 102 genes in C4, C3, C2, and C1 vs. C5 comparisons, respectively), 6 
further supporting the sequential activation of autoreactive CD8+ T cells in this order (Fig. 3, A and B, 7 
and Supplemental Figs. 3 and 4). The expression levels of Klf2, Ccr7, Lef1, and Id3 were decreased in 8 
C4 compared with C5 but increased in C3 (Fig. 3C and Supplemental Fig. S5). Because these genes 9 
have been reported to show a biphasic expression pattern with transient down-regulation in the initial 10 
phase of T cell activation [36-40], C4 likely represents primed cells that have immigrated from draining 11 
lymph nodes and C3 represents re-activated cells in islets.  12 
 At the transition from C4 to C3, we found the up-regulation of a variety of genes including those 13 
related to activation (e.g., Cd5 and Cd44), migration (e.g., Ccl3 and Selplg), and proliferation (e.g., 14 
Cd38, Foxo1, and Cdk4) (Fig. 3D and Supplemental Fig. S5). FoxO1 has been reported to hinder the 15 
effector differentiation of CD8+ T cells by up-regulating Pdcd1 [41, 42], suggesting that the activation 16 
of CD8+ T cells was attenuated by FoxO1–PD-1 axis at C3, which is in agreement with the interruption 17 
of the C3 to C2 transition by PD-1 among PD1posC cells as mentioned above (Fig. 1G). Upon 18 
transition to C2, more diverse genes including those related to effector function (e.g., Gzma and Gzmb) 19 
and cytokine signaling (e.g., Stat3 and Akt1) were up-regulated, indicating that autoreactive CD8+ T 20 
cells acquire effector function at this step and PD-1 particularly prohibits the acquisition of effector 21 
function by autoreactive CD8+ T cells (Fig. 3E and Supplemental Fig. S5). C1 cells likely include 22 
terminal effector and precursors of memory CD8+ T cells because the expression of genes related to 23 
terminal effector and memory T cells such as Cd27, Il2rb, Akt1, Id2, and Batf were markedly increased 24 
at this step (Fig. 3F and Supplemental Fig. S5)[43-45].  25 
 26 
3.5. PD-1+CD8+ autoreactive T cells subjected to PD-1 blockade are functionally enabled  27 
None of the genes examined was significantly up-regulated in C6 cells compared with C1–4 cells and 28 
only two genes, Ccl5 and Klrc1 showed significant up-regulation in C6 cells compared with C5 cells 29 
(Fig. 4A). Interestingly, the difference in Pdcd1 expression between C6 and C5 cells was not 30 
statistically significant, although the majority of C6 cells but not C5 cells expressed PD-1 protein on 31 
their cell surface. This discrepancy is most likely due to the generation of mRNA prior to protein and 32 
the differences in the stabilities of Pdcd1 mRNA and PD-1 protein. Nonetheless, C6 cells expressed 33 
substantial number of genes related to metabolism, proliferation, and signal transduction such as Idh2, 34 
Mdh2, and Akt2 at comparable levels (-2 < FC < 2) with C1–4 and C5 cells, indicating that C6 cells 35 
maintain the basal metabolic, proliferative, and signaling capacities (Fig. 4B and Supplemental Fig. S6). 36 
Against our initial expectation that C6 cells may represent Tex-like cells, they did not substantially 37 
express genes related to exhausted, anergic, and senescent T cells, suggesting that C6 cells are 38 
intensively inactivated but are different from Tex cells (Fig. 4C)[33, 46, 47]. 39 
 The expression of multiple inhibitory receptors such as PD-1, Tim-3, LAG-3, and BTLA is widely 40 
regarded as a hallmark of T cell exhaustion [33]. In the current study, the frequency of cells expressing 41 
multiple inhibitory receptors among PD-1+ cells was increased by PD-1-blockade (Fig. 4D). However, 42 
 9 
cells with multiple inhibitory receptors were concentrated in C1–2 cells and preferentially expressed 1 
multiple cytokines (Fig. 4D–F), indicating that these cells had escaped from the suppression by 2 
inhibitory receptors and were activated. Hereafter, we call C1 and C2 cells as T enabled (Ten) cells, 3 
because these cells were not exhausted but functionally enabled by PD-1 blockade.  4 
 Although C1–2 Ten cells were highly activated by escaping PD-1 suppression, not all C1–2 Ten 5 
cells expressed effector molecules. So, we explored genes that were differentially expressed in C1–2 6 
Ten cells with or without Gzma/Gzmb-expression (Fig. 4G). Among inhibitory molecules, Btla and 7 
Cd160 but not Lag3, Ctla4, and Pdcd1 were highly expressed in activated C1–2 Ten cells without 8 
Gzma/Gzmb expression, suggesting that BTLA and CD160 may play complementary roles in the 9 
suppression of autoreactive CD8+ T cells when PD-1 function is blocked. The expression of Havcr2 10 
(Tim-3) and Cd244 (2B4) was rather higher in C1–2 Ten cells expressing effector molecules, 11 
suggesting that these receptors may function in the ensuing phase. Meanwhile, C1–2 Ten cells without 12 
Gzma/Gzmb expression likely represent memory-precursors because they highly expressed 13 
memory-related genes such as Eomes, Cd27, Il2rb, and Ccr7 [44].    14 
 15 
3.6. Cluster composition of autoreactive CD8+ T cells correlates with disease status of T1D in 16 
NOD mice 17 
Then we examined the pathological consequence of the shifts in cluster composition. Because there are 18 
substantial interindividual differences in the progression of T1D in NOD mice, we examined the 19 
possible correlation between the cluster composition and the severity of insulitis among individual 20 
pre-diabetic NOD mice. We clustered islet-infiltrating PD-1+CD8+ T cells into five groups by using 21 
k-means++ based on the flowcytometric data, because PD-1+CD8+ T cells were mostly divided into five 22 
clusters (i.e., C1 to C4 and C6) in the aforementioned single-cell gene expression analyses (Fig. 1). 23 
When we visualized these cells by t-SNE, five groups of cells were clearly separated (Fig. 5, A and B). 24 
We designated these five groups as C1–4 and C6-like clusters based on expression profiles of molecules. 25 
The frequencies of C1- and C2-like Ten cells were higher while the frequencies of C4-, and C6-like 26 
cells were lower in mice treated with anti-PD-L1 Ab in consistent with the results of single-cell gene 27 
expression analyses (Fig. 5C). We evaluated the destruction of β cells and the severity of insulitis by 28 
quantifying the expression of genes related to β cells and lymphocytes in the pancreatic cell suspension 29 
of the same mouse. The expression levels of Ins1 and Gcg but not Amy2a and Lpl that represent 30 
exocrine cells in pancreata showed negative- and positive-correlations to the frequencies of C1/2-like 31 
Ten and C6-like cells, respectively (Fig. 5D). Thus, mice with more C1/2-like Ten cells maintained less 32 
β cells. The expression levels of Cd3e, Cd38, Ifng, Prf1, Gzma, and Gzmb showed positive and negative 33 
correlations to the frequencies of C1/2-like Ten and C6-like cells, respectively. These results 34 
demonstrate that the activation status of CD8+ T cells markedly reflects the destruction of β cells and the 35 
severity of insulitis.  36 
 37 
3.7. Tumor-specific T cells are activated in a similar trajectory found in T1D to destroy 38 
tumor-tissues in human melanoma patients upon anti-PD-1 therapy 39 
Finally, we examined the possible involvement of a similar activation trajectory in tumor-specific T 40 
cells of human patients receiving anti-PD-1 therapy (Fig. 6A). We hypothesized that tumor-specific T 41 
cells are activated in a similar trajectory found in T1D to destroy tumor-tissues. To test this hypothesis, 42 
 10 
we analyzed the data deposited by Chan and colleagues (GSE91061), in which the expression of genes 1 
in tumor-tissues before and after anti-PD-1 therapy and the responses of patients were collected [21]. 2 
Remarkably, genes representing the signature of C1–2 Ten cells (i.e., genes highly expressed in C1–2 3 
Ten cells compared with C3–4 cells) showed higher expression in melanoma tissues of responders 4 
compared with those of non-responders after anti-PD-1 therapy (Fig. 6, B and C). These results indicate 5 
that tumor specific T cells need to be activated upon anti-PD-1 therapy in a similar trajectory found in 6 
T1D to destroy tumor tissues efficiently.  7 
 We also hypothesized that the cluster composition of tumor-specific T cells before anti-PD-1 8 
therapy influence the efficacy of the therapy. We picked up genes that represent the signature of cells 9 
with active suppression by PD-1 (i.e., genes highly expressed in C3–4 compared with C6 cells) and 10 
examined their expression in tumor-tissues before anti-PD-1 therapy. Intriguingly, genes representing 11 
the relative increase of C3–4 over C6 showed higher expression in melanoma tissues of responders 12 
compared with those of non-responders before anti-PD-1 therapy (Fig. 6D–F). These results indicate 13 
that anti-PD-1 therapy is more efficacious when tumor-infiltrating cells are actively suppressed by PD-1 14 
(i.e., at C3–4) but are not functionally impaired (i.e., at C6) before the start of anti-PD-1 therapy. Thus, 15 
the cluster composition of T cells and the expression of genes representing the activation trajectory of 16 
CD8+ T cells in tumor tissues can be useful prognostic-markers for anti-PD-1 therapy. 17 
 18 
4. Discussion 19 
In the current study, we delineated the activation trajectory of autoreactive CD8+ T cells in T1D by 20 
comparing autoreactive CD8+ T cells under or beyond the control of PD-1. Autoreactive CD8+ T cells 21 
went through four activation-phases and PD-1 strongly attenuated the transition from the second- to the 22 
third-phase, where autoreactive CD8+ T cells acquired effector function. We detected the up-regulation 23 
of Foxo1 in C3 cells where the stepwise activation was suspended by PD-1. Because FoxO1 has been 24 
reported to hinder the effector differentiation of CD8+ T cells by up-regulating Pdcd1 [41, 42], FoxO1–25 
PD-1 axis may partly explain the interruption of the activation trajectory at C3 in the PD-1-sufficient 26 
condition. The majority of autoreactive CD8+ T cells under the control of PD-1 showed an intensively 27 
inactivated signature and exhibited a distinct trajectory in pseudotemporal ordering. 28 
 The shifts in cluster composition markedly reflected the damage of target tissues and the severity 29 
of inflammation in T1D of NOD mice. In addition, genes that were up-regulated along with the 30 
activation trajectory in T1D showed higher expression in melanoma tissues of responders compared 31 
with those of non-responders in anti-PD-1 therapy, indicating that tumor specific T cells can destroy 32 
tumor-tissues efficiently in human melanoma patients upon anti-PD-1 therapy when they are 33 
successfully activated in a similar trajectory found in T1D. Besides, genes representing cells with the 34 
active but not intensive suppression by PD-1 showed higher expression in melanoma tissues of 35 
responders compared with those of non-responders before the start of anti-PD-1 therapy, which is in 36 
agreement with the higher abundance of partially exhausted tumor-infiltrating CD8+ T cells in 37 
responders of anti-PD-1 therapy in the former study [19]. Thus, the fine clustering of tumor-specific T 38 
cells before anti-PD-1 therapy can be a useful strategy to predict the efficacy of anti-PD-1 therapy. 39 
Because of the limited response rates of anti-PD-1 therapy, markers to distinguish responders from 40 
non-responders are extensively explored [18-21, 48, 49]. By delineating the activation trajectory of 41 
CD8+ T cells upon PD-1 blockade, we could identify genes that accurately signify the activation status 42 
 11 
of CD8+ T cells and demonstrate their potencies as predictive markers. 1 
 Today, the role of PD-1 as a suppressor of T cells is widely accepted and anti-PD-1 therapy is used 2 
worldwide. However, how CD8+ T cells are activated to eradicate tumor cells or damage self-tissues 3 
upon anti-PD-1 therapy remain unclear. Actually, the increase of exhausted rather than activated CD8+ 4 
T cells in tumor tissues have been observed as hallmarks of PD-1-blockade at single cell level, which is 5 
rather paradoxical to its curative effect. Wei et al. reported that CD8+ T cells with Tex-like features were 6 
increased by anti-PD-1 therapy in tumors of mice and human patients using mass-cytometry [23]. 7 
Gubin et al. also reported the increase of cells with the lowest Gzmb expression upon PD-1 blockade in 8 
mice using mass-cytometry [24]. On the other hand, Sade-Feldman et al. identified 9 
memory/effector-like clusters of CD8+ T cells whose frequencies were higher in melanoma tissues of 10 
responders compared with non-responders in anti-PD-1 therapy using single-cell RNA sequencing [25]. 11 
However, they reported that there was no significant change between before and after anti-PD-1 therapy, 12 
indicating that the differences were likely related to features of tumors and/or microenvironments rather 13 
than PD-1 blockade itself. Although single-cell RNA sequencing is a very powerful method, the 14 
sensitivity for the detection of low-expressing genes is rather low, which may limit the fine 15 
characterization of cells. Thus, the activation of CD8+ T cells upon anti-PD-1 blockade has not been 16 
evident in former single cell analyses contrary to the general expectations, making the cellular 17 
mechanisms of tumor-eradication and irAEs by anti-PD-1 therapy remain to be clarified. 18 
 Compared with mass-cytometry and single-cell RNA sequencing, the current method has a 19 
limitation in the number of analyzable cells but has a better sensitivity for the detection of genes with 20 
relatively low expression [50]. In pre-diabetic NOD mice, autoreactive CD8+ T cells were readily 21 
activated and destroyed pancreateatic β cells upon PD-1 blockade. Because a substantial proportion but 22 
not all of islet-infiltrating CD8+ T cells proliferated upon PD-1 blockade, islet-infiltrating CD8+ T cells 23 
were likely composed of cells at diverse stages of the activation and cell cycle. We took the advantage 24 
of this rapid induction of T1D and analyzed autoreactive CD8+ T cells just before they completely 25 
eradicate β cells. Remarkably, we could detect autoreactive CD8+ T cells with 4 different activation 26 
phases among no more than 175 cells, indicating that the activation of autoreactive CD8+ T cells is a 27 
rapid and dynamic process. These results highlight the importance of pinpointing CD8+ T cells that are 28 
being activated and quantifying functionally relevant genes for the elucidation of the actual activation 29 
status of CD8+ T cells especially in anti-PD-1 therapy.  30 
 Our current findings revealed the activation trajectory of autoreactive CD8+ T cells in the target 31 
tissue and clearly demonstrated the rapid and massive increase of activated T cells by PD-1-blockade, 32 
which parallels with disease progression. Precise and deeper understandings of PD-1 effects on the 33 
activation trajectory of T cells are expected to elucidate the pathomechanisms of spontaneous as well as 34 
anti-PD-1 related autoimmune diseases and facilitate the rational design of immunotherapies. 35 
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Supplemental Table 1 1 
Gene   Forward primer (5' to 3')    Reverse primer (5' to 3') 2 
Gzmb   ACAGAAGGATCGGGAGTGTG  CTATGCCTGCAGCCACTTTT 3 
Gzma   GGCCATCTCTTGCTACTCTCC  GAACAACCGTGTCTCCTCCAA 4 
Prf   TAGCCAATTTTGCAGCTGAG  GGTTTTTGTACCAGGCGAAA 5 
Ifng   CCACGGCACAGTCATTGAAA  GCCAGTTCCTCCAGATATCCAA 6 
Cd3e   CTGCTACACACCAGCCTCAA  ATCAGCAAGCCCAGAGTGAT 7 
Cd38   CGCTGCCTCATCTACACTCA  GCAAGGGTTCTTGGAAACAA 8 
Lpl   GGGAGTTTGGCTCCAGAGTTT  TGTGTCTTCAGGGGTCCTTAG 9 
Amy2a2, 3, 4, 5 TAAAGTGGCTGACAAAGCCC  AGCCTTTTTCAAACTGGTGG 10 
Gcg   TGGTGCTCATCTCGTCAGAG  TGAATTTGAGAGGCATGCTG 11 
Ins1   CCTGTTGGTGCACTTCCTA   TCTGAAGGTCCCCGGGGCT 12 
 13 
Supplemental Table 1. Primer sets for real-time quantitative PCR in Fig. 5. 14 
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Fig. 1. Clustering of autoreactive CD8+ T cells under and beyond the control of PD-1. (A) Pathogenic role of CD8+ 
T cells in the rapid manifestation of T1D in pre-diabetic NOD mice upon PD-1-blockade. Diabetic incidence of 
NOD mice treated with αPD-L1 or its isotype control (ctrl Ig) (n = 8 each)(left). Diabetic incidence of NOD mice 
depleted of CD4+ (αCD4) or CD8+ (αCD8) T cells upon αPD-L1 treatment (n = 5 each)(right). (B) Preparation of 
PD-1+CD8+ T cells under or beyond PD-1 control. Schematic representation of the sample preparation (top). 
PD-1+CD8+ T cells from αPD-L1-treated NOD mice (PD1posA) and PD-1+CD8+ and PD-1–CD8+ T cells from 
control NOD mice (PD1posC and PD1negC, respectively) were analyzed (bottom). (C) Heat map showing 
k-means++ clustering of PD1posA, PD1posC, and PD1negC cells. A total of 175 single cells were clustered based 
on the expression of 139 genes. (D–F) PCA of single cells. Source (D) and cluster (E) of each cell are shown by 
color as indicated. Correlations of genes with the principal component 1 (PC1) and PC2 from the PCA are shown 
(F). (G) Cluster compositions of PD1posA, PD1posC, and PD1negC cells. ND, not detected. 
Fig. 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Activation trajectories of autoreactive CD8+ T cells revealed by the pseudotemporal ordering. (A–D) 
Pseudotemporal ordering of single cells. Projection into a two-dimensional space (A and B) and tree structure (C 
and D) by Monocle 2. Four states (Sa to Sd) and two branches (1 and 2) are indicated. Cluster (A) and origin (B) of 
cells are colored as indicated. Tree structures of C1–6 cells are separately shown (D). (E–G) Changes in naive and 
activated signatures of cells along with the reconstructed trajectory. Number of cells (top) and naive and activated 
(Act.) signatures (sig.) of each cell (middle and bottom) plotted with respect to pseudotime and pseudotime-order, 
respectively. Trajectories from Sa to Sb (E), Sa to Sd (F), and Sa to Sc (G) are shown. Cluster of cells are shown by 
color as indicated.  
  
Fig. 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. PD-1 prohibited autoreactive CD8+ T cells from acquiring effector function. (A and B) Sequential 
up-regulation of genes related to T cell activation in the order of C4 to C1. Volcano plots showing differentially 
expressed genes between C5 and C4–1 cells (A). Stacked bar graphs indicating the number of genes that were 
up-regulated in C4–1 cells compared with C5 cells. Genes up-regulated more than 2 folds (p < 0.05, ANOVA test) 
were counted. The number of genes that was additively up-regulated at the indicated comparison is shown with the 
indicated color (B). (C–E) Heat maps showing the relative expression levels of indicated genes among indicated 
clusters. Levels of down expression (blue) or up expression (red) are shown on a normalized z-score of each gene 
among C1–6 (C) and C1–4 cells (D and E). Up-regulated and down-regulated genes in the comparison between C4 
and C5 are shown (C). Genes up-regulated in the transition from C4 to C3 (D) and C3 to C2 (E) are shown. (F) 
Violin plots showing the expression of genes that were highly up-regulated in the transition from C2 to C1.   
Fig. 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Preferential expression of effector molecules by cells with multiple inhibitory receptors upon PD-1 blockade. 
(A) Volcano plots showing differentially expressed genes between C6 and C1–4 or C5 cells. (B) Substantial 
expression of genes related to metabolism, proliferation, and signal transduction by C6 cells. Violin plots showing 
the expression of indicated genes in C1–6 cells. (C) No up-regulation of genes related to exhaustion, senescent, and 
anergy in C6 cells. Heat maps showing the relative expression levels of indicated genes. Levels of down expression 
(blue) or up expression (red) are shown on a normalized z-score of each gene. (D–F) The expression of multiple 
inhibitory receptors (Pdcd1, Havcr2, Lag3, Btla, and Klrc1) and effector molecules (Gzma, Gzmb, Ifng, and Tnf) by 
highly activated T cells upon PD-1 blockade. The frequencies of cells expressing indicated numbers of inhibitory 
receptors and effector molecules are shown for each cluster (D). The frequencies of cells expressing indicated 
numbers of effector molecules are shown for cells expressing indicated numbers of inhibitory receptors (E). The 
correlation coefficients of co-expression were evaluated by nearest-neighbor analysis for indicated gene sets (F). (G) 
Differentially expressed genes between C1–2 cells with or without effector molecules. Fold-change expression of 
indicated genes between C1–2 cells double-positive (DP, red) or -negative (DN, blue) for Gzma and Gzmb are 
shown in log2 scale. Genes showed higher expression in DP and DN cells are colored in red and blue, respectively.   
Fig. 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Correlation between cluster composition and disease status of T1D in NOD mice. (A) Schematic 
representation of the sample preparation. Pancreatic cell suspension was divided into two for flowcytometry (FCM) 
and quantitative PCR. (B) Classification of PD-1+CD8+ T cells into C1-, C2-, C3-, C4-, and C6-like clusters. A 
t-SNE plot of islet-infiltrating PD-1+CD8+ T cells overlaid with the color-coded clusters (left). Density t-SNE plots 
of islet-infiltrating PD-1+CD8+ T cells from NOD mice treated with (middle, n = 4) or without (right, n = 17) 
αPD-L1. (C) Increase of C1- and C2-like cells and decrease of C4- and C6-like cells by PD-1 blockade. (D) 
Correlation between cluster composition and disease status. Frequencies of C1- and C2-like (top) and C6-like 
(bottom) cells are shown for mice with higher (black) and lower (gray) expression of indicated genes. Two-tailed 
paired Student's t-test (C and D). *P < 0.05, **P < 0.01, ***P < 0.005. 
Fig. 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Tumor-specific T cells are activated in a similar trajectory found in T1D to destroy tumor-tissues in human 
melanoma patients upon anti-PD-1 therapy. (A) Schematic representation of the two hypotheses. Anti-PD-1 therapy 
is expected to be more efficacious when tumor-infiltrating T cells are actively suppressed by PD-1 (i.e., at C3–4) but 
are not functionally impaired (i.e., at C6) before anti-PD-1 therapy (left). Anti-PD-1 therapy is expected to enable 
tumor specific T cells in a similar activation trajectory found in T1D in responders of anti-PD-1 therapy (middle). 
The activation trajectory of autoreactive CD8+ T cell upon anti-PD-1 therapy in NOD mice is shown in the right 
side. (B and C) Genes representing the progression of the activation trajectory in T1D showed higher expression in 
melanoma-tissues of responders upon anti-PD-1 therapy. Bar graphs showing the expression levels of indicated 
genes in C1–2 and C3–4 cells (B). Box plots showing the expression levels (FPKMs) of indicated genes in 
melanoma-tissues upon anti-PD-1 therapy (C). (D–F) Genes representing the dominance of C3–4 over C6 in T1D 
showed higher expression in melanoma-tissues of responders before anti-PD-1 therapy. Bar graphs showing the 
expression levels of indicated genes in C3–4 and C6 cells (D). Box plots showing the expression levels of indicated 
genes in melanoma-tissues before anti-PD-1 therapy. Genes with higher (E) or comparable (F) expression levels in 
C3–4 cells compared with C6 cells are shown. PD, progressive disease (n = 18); SD, stable disease (n = 15); PR, 
partial response (n = 6); CR, complete response (n = 3) (C, E, and F).    
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Supplemental Fig. 1. Activation of diabetogenic T cells in islets upon PD-1 blockade. (A) Increase of PD-1 
expressing CD8+ T cells in islets upon PD-1 blockade. Pre-diabetic NOD mice were treated with (n = 7) or without 
(n = 4) αPD-L1 on days 0 and 2. PD-1 expression on CD8+ T cells in islets, pancreatic LNs, and spleens were 
examined on day 4. (B) Increase of proliferating CD8+ T cells in islets upon PD-1 blockade. Pre-diabetic NOD mice 
were treated with (n = 7) or without (n = 5) αPD-L1 on days 0 and 2 and EdU on day 2. EdU-incorporation of CD8+ 
T cells in islets, pancreatic LNs, and spleens were examined on day 4. Two-tailed paired Student's t-test. *P < 0.05, 
**P < 0.01, ***P < 0.005. 
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Supplemental Fig. 2. Activation trajectories of PD1posA, PD1posC, and PD1negC cells. (A) Pseudotemporal 
ordering of PD1posA, PD1posC, and PD1negC cells projected into a two-dimensional space. Four states (Sa to Sd) 
and two branches (1 and 2) are indicated. (B) The correlations between C1–C6 and Sa–Sd among total, PD1posA, 
PD1posC, and PD1negC single cells. 
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Supplemental Fig. 3. Up-regulated genes in C4–1 cells compered with C5 cells. (A) Genes that were up-regulated 
more than 2 folds in C4 cells compared with C5 cells. (B) Genes that were up-regulated more than 2 folds in C3 
cells compared with C5 cells. (C) Genes that were up-regulated more than 2 folds in C2 cells compared with C5 
cells. (D) Top 50 genes that were up-regulated in C1 cells compared with C5 cells. FC expression of indicated genes 
between cells with indicated clusters are shown in a log2 scale.  
Supplemental Fig. 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Fig. 4. Down-regulated genes in C4–1 cells compered with C5 cells. (A) Genes that were 
down-regulated more than 2 folds in C4 cells compared with C5 cells. (B) Genes that were down -regulated more 
than 2 folds in C3 cells compared with C5 cells. (C) Genes that were down -regulated more than 2 folds in C2 cells 
compared with C5 cells. (D) Genes that were down -regulated more than 2 folds in C1 cells compared with C5 cells. 
FC expression of indicated genes between cells with indicated clusters are shown in a log2 scale.  
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Supplemental Fig. 5. Up-regulated genes at the transition from C4 to C1. (A) Genes that were up-regulated more 
than 2 folds in C3 cells compared with C4 cells. (B) Genes that were up-regulated more than 2 folds in C2 cells 
compared with C3 cells. (C) Top 50 genes that were up-regulated in C1 cells compared with C2 cells. FC 
expression of indicated genes between cells with indicated clusters are shown in a log2 scale.  
Supplemental Fig. 6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Fig. 6. Genes expressed comparably in C6 cells compared with C1–4 and C5 cells. (A) Genes that 
were expressed comparably (|FC| < 2) in C6 cells compared with C1–4 cells. (B) Genes that were expressed 
comparably (|FC| < 2) in C6 cells compared with C5 cells. FC expression of indicated genes among C6 cells 
compared with C1–4 (A) and C5 (B) cells are shown in a log2 scale. 
